I believe the gist of it is: FDA is willing to accept new potency data generated to pave the way for FDA to consider pH 3 trial MAB-GVHD001 gor paediatrics as adequate study. I think (a) a few months is quite a good time frame for a potentially significant outcome.
Re adults, a 12 month controlled single arm is also quite a reasonable outcome and given the data and evidence already, that should be a matter of ticking the box ... something FDA likes.
So, much better than we could have potentially ntcipated.
Ann: Mesoblast Type A Meeting with FDA, page-8
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
91.5¢ |
Change
-0.010(1.08%) |
Mkt cap ! $1.044B | |||
| Open | High | Low | Value | Volume |
| 94.0¢ | 94.0¢ | 91.5¢ | $1.609M | 1.737M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 131951 | 91.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 92.5¢ | 22000 | 1 |
View Market Depth
| Last trade - 16.10pm 10/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |